Evaxion

The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)

Talos

Invested

Community Contributor

Published

02 Dec 25

Updated

07 May 26

Views

162

07 May

US$4.08

Talos's Fair Value

US$20.25

79.9% undervalued

117.0%

4.1%

117.0%

4.1%

You can edit this narrative until May 8 10:00 PM. Then, changes will post as Updates.

Author's Valuation

US$20.2579.9% undervalued

Talos's Fair Value

Shared on 07 May 26

Fair value Increased 28%

Talos has increased revenue growth from 13.8% to 67.3%, increased future PE multiple from 30.0x to 35.0x and decreased timeframe from 5 years to 3 years.

21 views

Valuator

Company Info

Notes

Talos'sFair Value

US$20.25

79.9% undervalued

Future estimation in

Revenue

Profit Margin

Future PE

Est. Revenue

Forecast revenue growth rate

28.01%

Historical revenue growth rate

83.35%

Biotech revenue growth rate

11.07%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.92%

Calculation

US$14.11m

Earnings '29

35.00x

PE Ratio '29

US$493.95m

Market Cap '29

US$493.95m

Market Cap '29

18.32m

No. shares '29

US$26.96

Share Price '29

US$26.96 Share Price '29

Discounted to 2026 @ 10.00% p.a.

US$20.25

Fair Value '26